Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Completed · Phase 1

Conditions studied: Hepatitis B Virus

In brief

The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.

Key facts

Study ID

NCT02296853

Run by

Gilead Sciences

People needed

20

Starts

2014-12-22

Expected to finish

2015-04-17

Last updated by the study team

2020-12-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

Where it is running

• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — San Antonio, Texas, United States
• Study site — Munich, Germany
• Study site — Gratton, Auckland, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.